7Baggers

Evolus, Inc
(NASDAQ:EOLS) 

EOLS stock logo

Evolus, Inc., a performance beauty company, provides products in the self-pay aesthetic healthcare market for physicians and their patients in the United States. The company offers products for physicians that are sold to consumers or used in procedures for aesthetic indications, which are not reimb...

Founded: 2012
Full Time Employees: 125
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 
                                     
      revenue:
    		                                 
      product revenue
    		89,216,000 68,967,000 68,699,000 68,074,000 78,956,000 60,164,000 66,222,000 58,964,000 60,671,000 49,323,000 48,680,000 41,047,000 42,988,000 33,215,000 37,163,000 33,226,000 34,657,000 26,677,000 25,396,000 12,241,000 20,577,000 16,923,000            
      service revenue
    		1,084,000  688,000 448,000 -9,000 921,000 687,000 369,000 328,000 696,000 666,000 674,000 658,000 684,000  682,000   702,000   738,000            
      total net revenues
    		90,300,000 68,967,000 69,387,000 68,522,000 78,947,000 61,085,000 66,909,000 59,333,000 60,999,000 50,019,000 49,346,000 41,721,000 43,646,000 33,899,000 37,163,000 33,908,000 34,657,000 26,677,000 26,098,000  20,577,000 17,661,000            
      cost of goods sold
    		31,009,000 23,126,000 24,067,000 21,867,000                              
      gross profit
    		59,291,000 45,841,000 45,320,000 46,655,000                 6,235,500 12,807,000 5,858,000 6,277,000 15,811,000 9,449,000 1,651,000       
      yoy
    		                    -60.56% 35.54% 254.82%           
      qoq
    		29.34% 1.15% -2.86%                  -51.31% 118.62% -6.68% -60.30% 67.33% 472.32%        
      operating expenses:
    		                                 
      selling, general and administrative
    		54,655,000 52,816,000 56,675,000 56,640,000 50,244,000 52,506,000 50,152,000 45,123,000 43,058,000 43,328,000 41,174,000 37,384,000 36,729,000 34,794,000 36,875,000 33,442,000 33,234,000 31,685,000 26,472,000 20,677,000 27,394,000 21,944,000 17,553,000 31,300,000 30,285,000 30,897,000 34,892,000       
      research and development
    		3,481,000 2,046,000 1,837,000 2,212,000 2,430,000 2,314,000 2,350,000 2,078,000 2,380,000 1,587,000 1,208,000 1,381,000 1,348,000 1,376,000 1,550,000 468,000 423,000 301,000 499,000 841,000 719,000 350,000 145,000 507,000 418,000 693,000 509,000 2,353,000 1,184,000 1,977,000 1,648,000 1,678,000  
      revaluation of contingent royalty obligation payable to evolus founders
    		-4,511,000 -107,000 -3,914,000 2,151,000 1,565,000 2,428,000 1,605,000 1,578,000 -875,000 1,802,000 1,682,000 1,648,000 1,809,000 1,216,000 1,414,000 1,316,000 1,012,250 1,400,000 1,381,000 1,268,000 -2,480,500 -2,471,000 2,433,000 -9,884,000 1,994,250 1,795,000 1,269,000       
      depreciation and amortization
    		1,446,000 1,143,000 932,000 824,000 -1,581,000 1,087,000 1,427,000 1,409,000 1,373,000 1,311,000 1,247,000 1,202,000 1,027,000 920,000 853,000 922,000 920,000 923,000 1,746,000 2,033,000 1,876,000 1,744,000 1,658,000 1,749,000 1,468,000 1,202,000 978,000 484,000 2,000 3,000 4,000   
      restructuring costs
    		 1,443,000                     2,956,000           
      total operating expenses
    		55,071,000 57,341,000 55,530,000 61,827,000 -2,709,000 76,558,000 74,611,000 68,255,000 69,634,000 63,459,000 64,464,000 53,761,000 54,283,000 51,796,000 58,511,000 49,356,000 52,652,000 45,799,000 41,400,000 4,227,000 139,624,000 21,567,000 24,745,000 23,672,000 28,354,000 34,587,000 37,648,000 25,269,000 12,508,000 11,489,000 16,100,000 6,045,000  
      income from operations
    		4,220,000 -11,500,000 -10,210,000 -15,172,000 -2,314,000 -15,473,000 -7,702,000 -8,922,000 -8,635,000 -13,440,000 -15,118,000 -12,040,000 -10,637,000 -17,897,000 -21,348,000 -15,448,000 -17,995,000 -19,122,000 -15,302,000 8,014,000 -108,026,000 -8,760,000 -18,887,000 -17,395,000 -12,543,000 -25,138,000 -35,997,000 -25,269,000 -12,508,000 -11,489,000 -16,100,000 -6,045,000  
      yoy
    		-282.37% -25.68% 32.56% 70.05% -73.20% 15.13% -49.05% -25.90% -18.82% -24.90% -29.18% -22.06% -40.89% -6.41% 39.51% -292.76% -83.34% 118.29% -18.98% -146.07% 761.25% -65.15% -47.53% -31.16% 0.28% 118.80% 123.58% 318.01%      
      qoq
    		-136.70% 12.63% -32.70% 555.66% -85.04% 100.90% -13.67% 3.32% -35.75% -11.10% 25.56% 13.19% -40.57% -16.17% 38.19% -14.15% -5.89% 24.96% -290.94% -107.42% 1133.17% -53.62% 8.58% 38.68% -50.10% -30.17% 42.46% 102.02% 8.87% -28.64% 166.34%   
      other income:
    		                                 
      interest income
    		263,000 479,000 479,000 710,000 789,000 928,000 1,029,000 517,000 291,000 306,000 164,000 99,000 77,000 38,000 4,000    1,000  5,000 32,000 224,000 374,000 375,000 460,000 615,000 389,000      
      interest expense
    		-3,978,000 -4,094,000 -7,207,000 -4,415,000 -4,573,000 -4,764,000 -4,696,000 -4,702,000 -4,075,000 -3,786,000 -3,182,000 -2,789,000 -2,631,000 -2,343,000 -2,075,000 -2,048,000 -140,000 -311,000 -300,000 -645,000 -2,823,000 -2,758,000 -2,464,000 -2,458,000 -2,468,000 -2,455,000 -2,412,000 -618,000 -1,613,000 322,000 321,000 107,000  
      other income
    		10,000 -455,000 -151,000 57,000 -253,000 273,000 62,000 45,000 694,000 21,000 19,000                       
      income before income taxes
    		515,000 -15,570,000 -17,089,000                         -25,498,000      
      income tax expense
    		-385,000 -167,000 -53,000 72,000 440,000 134,000 43,000 47,000 106,000 24,000 23,000 23,000 57,000 12,000 28,000 -2,000     -150,000 -27,000 -2,000 256,000 -128,000 -149,000 -227,000 -14,523,000 10,250 19,000 12,000 10,000  
      net income
    		130,000 -15,737,000 -17,142,000 -18,892,000 -6,791,000 -19,170,000 -11,350,000 -13,109,000 -11,831,000 -16,923,000 -18,140,000 -14,791,000 -13,164,000 -20,276,000 -23,471,000 -17,501,000 -18,177,000 -19,433,000 -15,601,000 6,401,000 -110,694,000 -11,459,000 -21,125,000 -19,735,000 -14,508,000 -26,984,000 -37,567,000 -10,975,000      
      yoy
    		-101.91% -17.91% 51.03% 44.11% -42.60% 13.28% -37.43% -11.37% -10.13% -16.54% -22.71% -15.48% -27.58% 4.34% 50.45% -373.41% -83.58% 69.59% -26.15% -132.43% 662.99% -57.53% -43.77% 79.82%          
      qoq
    		-100.83% -8.20% -9.26% 178.19% -64.57% 68.90% -13.42% 10.80% -30.09% -6.71% 22.64% 12.36% -35.08% -13.61% 34.11% -3.72% -6.46% 24.56% -343.73% -105.78% 866.00% -45.76% 7.04% 36.03% -46.23% -28.17% 242.30%       
      other comprehensive income, net of tax:
    		                                 
      currency translation adjustment
    		-19,000 462,000 240,000                               
      comprehensive loss
    		111,000 -15,275,000 -16,902,000 -18,826,000 -7,007,000 -19,258,000 -11,394,000 -13,239,000 -11,652,000 -17,061,000 -18,192,000 -14,870,000 -13,133,000 -20,479,000 -23,533,000  -18,177,000 -19,433,000 -15,601,000  -110,697,000 -11,475,000 -21,331,000 -19,516,000 -14,521,000 -27,008,000 -37,515,000 -10,984,000      
      net income per share
    		 -0.24 -0.27 -0.3 -0.1 -0.3 -0.18 -0.22 -0.2 -0.3 -0.32 -0.26 -0.24 -0.36 -0.42 -0.31 -0.34 -0.35 -0.31 0.17 -3.28 -0.34 -0.63 -0.59 -0.43 -0.98 -1.37 -0.4 -0.45 -0.48 -0.69 -0.3  
      weighted-average shares outstanding used to compute basic and diluted net loss per share
    		64,468,913 64,726,239 64,539,291 63,696,627 62,016,853 63,148,968 62,724,604 58,797,311 56,918,721 57,023,151 56,920,260 56,475,572 56,065,297 56,176,949 56,079,569  49,773,101 55,007,132 51,150,063  33,737,838 33,748,690 33,732,754 33,720,436 28,237,816 27,470,558 27,408,774 27,330,174 24,402,368 24,768,581 23,687,866 20,226,460  
      loss before income taxes:
    		   -18,820,000 -6,351,000 -19,036,000 -11,307,000 -13,062,000 -11,725,000 -16,899,000 -18,117,000 -14,768,000 -13,107,000 -20,264,000 -23,443,000  -7,158,250 -19,433,000 -15,601,000  -13,023,000 -11,486,000 -21,127,000 -19,479,000 -22,606,250 -27,133,000 -37,794,000       
      other comprehensive loss:
    		                                 
      unrealized income, net of tax
    		   66,000                              
      product cost of sales
    		    13,841,750 18,223,000 19,077,000 18,067,000 19,270,000 15,431,000 14,712,000 12,146,000 13,370,000 13,490,000 15,819,000 13,208,000 15,834,000 11,490,000 11,302,000 4,908,000              
      in-process research and development
    		        4,428,000  4,441,000    2,000,000                   
      unrealized loss, net of tax
    		    -216,000 -88,000 -44,000 -130,000 179,000 -138,000 -52,000 -79,000 31,000 -203,000                    
      other expense
    		           -38,000 84,000 -62,000 -24,000 -7,000                  
      settlement payment from daewoong
    		                   -25,500,000              
      loss from extinguishment of debts
    		                   -968,000              
      other comprehensive gain:
    		                                 
      unrealized gain
    		              -62,000 103,000                  
      income before income taxes:
    		               -17,503,000    6,401,000              
      comprehensive income
    		               -17,398,000    6,401,000              
      weighted-average shares outstanding used to compute basic net income per share
    		               55,731,217    37,100,897              
      weighted-average shares outstanding used to compute diluted net income per share
    		               55,731,217    41,104,627              
      unrealized loss on available-for-sale securities, net of tax
    		                           -9,000      
      unrealized gain on available-for-sale securities, net of tax
    		                    -3,000 -16,000 -206,000 219,000 -13,000 -24,000 52,000       
      cost of sales
    		                    2,755,250 4,854,000 1,948,000 4,219,000 1,094,500 3,718,000 660,000       
      net revenues
    		                      7,806,000 10,496,000 3,869,500 13,167,000 2,311,000       
      general and administrative
    		                           17,519,000 12,222,000 7,209,000 6,248,000 3,467,000  
      revaluation of contingent royalty obligation payable to evolus founders, a related party
    		                           4,913,000 2,850,000 2,300,000 8,200,000   
      other expense:
    		                                 
      loss before taxes
    		                            -12,418,000 -11,811,000 -16,421,000 -6,152,000  
      net loss and comprehensive loss
    		                            -12,442,000 -11,830,000 -16,433,000 -6,162,000  
      revaluation of contingent royalty obligation payable to related party
    		                               900,000  
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 
                                       
        assets
      		                                 
        current assets
      		                                 
        cash and cash equivalents
      		53,826,000 43,523,000 61,738,000 67,894,000 86,952,000 85,035,000 93,671,000 96,958,000 62,838,000 38,685,000 41,705,000 31,463,000 53,922,000 65,572,000 84,484,000 106,671,000 146,256,000 107,796,000 131,737,000 22,171,000 102,562,000 85,127,000 29,772,000 34,652,000 109,892,000 39,116,000 30,289,000 54,367,000    49,570,000  
        accounts receivable
      		54,697,000 50,435,000 47,709,000 47,454,000 47,682,000 44,642,000 43,149,000 34,240,000 30,529,000 30,464,000 28,996,000 23,455,000 22,448,000 20,920,000 21,026,000 16,800,000 14,657,000 13,289,000 11,864,000 7,816,000 9,680,000 11,399,000 8,649,000 10,406,000 10,661,000 7,206,000 1,410,000       
        inventories
      		26,963,000 32,871,000 26,457,000 10,026,000 12,158,000 14,892,000 13,381,000 11,547,000 10,998,000 17,626,000 19,859,000 23,418,000 18,852,000 21,565,000 12,289,000 3,615,000 1,762,000 3,816,000 3,337,000 2,775,000 3,354,000 4,871,000 10,343,000 12,542,000 6,407,000 10,043,000 11,522,000 2,578,000      
        prepaid expenses
      		3,757,000 4,604,000 4,792,000 3,452,000 3,349,000 3,399,000 5,507,000 5,678,000 5,700,000 3,655,000 4,297,000 4,159,000 3,902,000 3,656,000 4,724,000 4,533,000 5,082,000 4,484,000 5,737,000 5,464,000              
        other current assets
      		3,674,000 3,456,000 4,274,000 2,892,000 1,201,000 2,393,000 2,426,000 1,842,000 2,356,000 1,569,000 1,603,000 1,590,000 1,678,000 4,233,000 11,424,000 11,309,000 11,042,000 8,959,000 9,215,000 6,728,000              
        total current assets
      		142,917,000 134,889,000 144,970,000 131,718,000 151,342,000 150,361,000 158,134,000 150,265,000 112,421,000 91,999,000 96,460,000 84,085,000 100,802,000 115,946,000 133,947,000 142,928,000 178,799,000 138,344,000 161,890,000 77,717,000 127,612,000 132,400,000 107,998,000 126,142,000 152,197,000 95,184,000 115,826,000 139,084,000 94,339,000 106,092,000 44,623,000 50,111,000 72,824,000 
        property and equipment
      		5,371,000 5,131,000 3,653,000 3,254,000 3,222,000 2,314,000 2,284,000 2,088,000 2,087,000 2,130,000 2,353,000 2,595,000 2,616,000 1,882,000 1,455,000 1,303,000 1,371,000 1,058,000 1,137,000 1,217,000 1,297,000 1,362,000 1,422,000 1,433,000 902,000 984,000 290,000   1,000 5,000   
        operating lease right-of-use assets
      		7,133,000 7,468,000 7,827,000 6,922,000 7,185,000 8,280,000 5,462,000 5,615,000 5,763,000 5,907,000 1,523,000 1,738,000 1,947,000 2,149,000 2,346,000 2,537,000 2,722,000 2,902,000 3,078,000 3,248,000 3,414,000 3,578,000 3,738,000 3,899,000 4,068,000 4,238,000 5,040,000 810,000      
        intangible assets
      		48,040,000 48,719,000 49,347,000 49,359,000 48,754,000 46,587,000 46,275,000 46,591,000 47,110,000 46,505,000 47,216,000 47,927,000 48,597,000 49,108,000 49,415,000 50,032,000 50,625,000 51,468,000 52,310,000 53,568,000 55,297,000 56,791,000 58,023,000 59,174,000 59,638,000 59,857,000 59,211,000 58,782,000      
        goodwill
      		21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 21,208,000 
        other assets
      		1,199,000 1,582,000 1,798,000 900,000 858,000 858,000 409,000 409,000 409,000 222,000 223,000 2,682,000 2,813,000 2,426,000 2,548,000 2,654,000 2,758,000 240,000 240,000 240,000 240,000 440,000 2,155,000 2,295,000 2,429,000 1,195,000 1,206,000 1,045,000 221,000  22,000  2,125,000 
        total assets
      		225,868,000 218,997,000 228,803,000 213,361,000 232,569,000 229,608,000 233,772,000 226,176,000 188,998,000 167,971,000 168,983,000 160,235,000 177,983,000 192,719,000 210,919,000 220,662,000 257,483,000 215,220,000 239,863,000 157,198,000 209,068,000 215,779,000 194,544,000 214,151,000 240,442,000 182,666,000 202,781,000 220,929,000 171,844,000 183,377,000 121,934,000 127,395,000 152,233,000 
        liabilities and stockholders’ equity
      		                                 
        current liabilities
      		                                 
        accounts payable
      		23,360,000 22,958,000 23,312,000 16,176,000 9,236,000 13,836,000 10,281,000 11,216,000 4,271,000 11,760,000 7,835,000 10,185,000 8,935,000 8,564,000 10,486,000 7,565,000 6,091,000 7,365,000 8,059,000 13,253,000 9,615,000 2,957,000 10,952,000 10,699,000 5,796,000 6,125,000  1,863,000 1,558,000 661,000 751,000 547,000 445,000 
        accrued expenses
      		35,591,000 30,462,000 27,949,000 26,619,000 40,791,000 34,949,000 32,790,000 25,054,000 33,813,000 26,713,000 24,184,000 22,109,000 24,794,000 29,883,000 28,537,000 21,139,000 29,993,000 23,436,000 24,357,000 12,567,000 9,102,000 6,425,000 6,094,000 9,403,000 13,960,000 14,378,000  6,735,000 3,718,000 4,799,000 2,933,000 2,352,000 977,000 
        current portion of operating lease liabilities
      		2,529,000 2,476,000 2,392,000                        1,031,000       
        current portion of contingent royalty obligation payable to evolus founders
      		12,523,000 10,815,000 10,097,000                               
        current portion of contingent milestone payment
      		1,302,000                                 
        total current liabilities
      		75,305,000 66,711,000 63,750,000 56,233,000 62,960,000 60,815,000 54,118,000 46,801,000 48,291,000 48,540,000 41,349,000 40,678,000 46,509,000 51,271,000 51,531,000 40,700,000 57,663,000 71,303,000 87,286,000 87,648,000 180,248,000 12,709,000 19,462,000 22,613,000 24,439,000 25,974,000 23,105,000 9,400,000 5,276,000 5,460,000 3,684,000 3,629,000 212,748,000 
        long-term portion of operating lease liabilities
      		6,371,000 6,636,000 7,039,000                               
        long-term portion of contingent royalty obligation payable to evolus founders
      		19,659,000 25,878,000 28,489,000                               
        long-term portion of term loan, net of discount and issuance costs
      		146,096,000 145,780,000 145,475,000                               
        long-term portion of contingent milestone payment
      		1,515,000                                 
        deferred tax liability
      		28,000  21,000 2,000 6,000 29,000 29,000 32,000 27,000 22,000 22,000 22,000 22,000 25,000 29,000 23,000 40,000 25,000 25,000 25,000 25,000 179,000 190,000 256,000  156,000 305,000 533,000 15,055,000 15,031,000 15,013,000 15,000,000 14,990,000 
        total liabilities
      		248,974,000 247,757,000 247,455,000 219,965,000 227,047,000 223,718,000 214,458,000 207,733,000 209,687,000 187,339,000 175,946,000 153,286,000 159,484,000 163,499,000 164,058,000 153,414,000 175,607,000 117,816,000 133,725,000 133,909,000 282,026,000 180,684,000 150,941,000 151,545,000 160,985,000 165,623,000 161,600,000 145,572,000 87,460,000 88,411,000 83,999,000 75,413,000 227,776,000 
        commitments and contingencies
      		                                 
        stockholders’ equity
      		                                 
        preferred stock, 0.00001 par value...
      		                                 
        common stock, 0.00001 par value...
      		1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000 1,000  
        additional paid-in capital
      		638,089,000 632,546,000 627,379,000 622,525,000 615,825,000 609,186,000 603,352,000 591,087,000 538,716,000 528,385,000 523,729,000 519,449,000 516,129,000 513,717,000 510,879,000 507,733,000 504,757,000 502,108,000 491,409,000 392,959,000 303,113,000 300,469,000 297,502,000 295,174,000 292,509,000 215,574,000 212,704,000 209,365,000 207,408,000 205,548,000 136,687,000 134,301,000  
        accumulated other comprehensive loss
      		-156,000 -137,000 -599,000 -839,000 -905,000 -689,000 -601,000 -557,000 -427,000 -606,000 -468,000 -416,000 -337,000 -368,000 -165,000 -103,000            -9,000      
        accumulated deficit
      		-661,040,000 -661,170,000 -645,433,000 -628,291,000 -609,399,000 -602,608,000 -583,438,000 -572,088,000 -558,979,000 -547,148,000 -530,225,000 -512,085,000 -497,294,000 -484,130,000 -463,854,000 -440,383,000 -422,882,000 -404,705,000 -385,272,000 -369,671,000 -376,072,000 -265,378,000 -253,919,000 -232,794,000 -213,059,000 -198,551,000 -171,567,000 -134,000,000 -123,025,000 -110,583,000 -98,753,000 -82,320,000 -75,543,000 
        total stockholders’ equity
      		-23,106,000 -28,760,000 -18,652,000 -6,604,000 5,522,000 5,890,000 19,314,000 18,443,000 -20,689,000 -19,368,000 -6,963,000 6,949,000 18,499,000 29,220,000 46,861,000 67,248,000 81,876,000 97,404,000 106,138,000 23,289,000  35,095,000 43,603,000 62,606,000 79,457,000 17,043,000 41,181,000 75,357,000 84,384,000 94,966,000 37,935,000 51,982,000  
        total liabilities and stockholders’ equity
      		225,868,000 218,997,000 228,803,000 213,361,000 232,569,000 229,608,000 233,772,000 226,176,000 188,998,000 167,971,000 168,983,000 160,235,000 177,983,000 192,719,000 210,919,000 220,662,000 257,483,000 215,220,000 239,863,000 157,198,000  215,779,000 194,544,000 214,151,000 240,442,000 182,666,000 202,781,000 220,929,000 171,844,000 183,377,000 121,934,000 127,395,000  
        contingent milestone payment
      		 2,752,000 2,681,000 2,416,000 2,270,000                             
        operating lease liabilities
      		   1,967,000 1,718,000 1,601,000 1,041,000 1,152,000 1,377,000 1,363,000 1,349,000 1,334,000 1,320,000 1,307,000 1,293,000 1,279,000 1,265,000 1,252,000 1,239,000 1,226,000 1,212,000 1,197,000 1,182,000 1,195,000 1,200,000 1,148,000 4,147,000 802,000      
        contingent royalty obligation payable to evolus founders
      		   11,471,000 11,215,000 10,429,000 10,006,000 9,379,000 8,830,000 8,704,000 7,981,000 7,050,000 6,460,000 6,517,000 6,215,000 5,717,000 5,314,000 4,300,000 3,983,000 3,985,000 3,446,000 2,130,000 1,234,000 1,316,000 3,483,000 4,323,000 43,773,000       
        term loan, net of discount and issuance costs
      		   121,807,000 121,506,000 121,208,000 120,918,000 120,636,000 120,359,000 95,094,000 94,829,000 72,046,000 71,879,000 71,712,000 71,545,000 71,381,000     74,384,000             
        accrued litigation settlement
      		            5,000,000 5,000,000 5,000,000 5,000,000 15,000,000 15,000,000 30,000,000 30,000,000              
        short-term investments
      		                    5,000,000 24,996,000 54,982,000 64,987,000 19,911,000 34,913,000 69,640,000 79,313,000      
        promissory note payable to evolus founders
      		                 19,950,000 19,648,000 19,354,000              
        convertible note
      		                    40,506,000 40,203,000            
        term loan, net of discounts and issuance costs
      		                     73,974,000            
        consideration receivable from daewoong
      		                   25,500,000              
        withholding tax receivable
      		                   7,263,000              
        withholding tax payable
      		                   7,263,000              
        prepaid expenses and other current assets
      		                    7,016,000 6,007,000 4,252,000 3,555,000 5,326,000 3,906,000 2,965,000 2,826,000 1,177,000 924,000 1,038,000 541,000 185,000 
        liabilities and stockholders’ (deficit) equity
      		                                 
        accrued litigation settlement expenses
      		                    63,421,000             
        contingent promissory note payable to evolus founders
      		                    19,068,000 18,779,000 18,495,000 18,218,000 17,945,000 17,674,000 17,408,000       
        stockholders’ (deficit) equity
      		                                 
        accumulated other comprehensive gain
      		                     3,000 19,000 225,000 6,000 19,000 43,000       
        total stockholders’ (deficit) equity
      		                    -72,958,000             
        total liabilities and stockholders’ (deficit) equity
      		                    209,068,000             
        long-term debt
      		                      74,165,000 73,841,000 73,508,000 73,180,000 72,862,000 72,557,000      
        deferred rent
      		                            25,000 29,000 32,000 35,000 38,000 
        accounts payable and accrued expenses
      		                          22,074,000       
        contingent royalty obligation payable to evolus founders, a related party
      		                           45,900,000 50,200,000 51,100,000 48,800,000   
        contingent promissory note payable to evolus founders, a related party
      		                           17,153,000 16,904,000 16,791,000 16,470,000   
        cash
      		                            93,162,000 105,168,000 43,585,000   
        related party receivable
      		                                72,639,000 
        intangible asset
      		                            56,076,000 56,076,000 56,076,000 56,076,000 56,076,000 
        related party borrowings
      		                                72,639,000 
        note obligation
      		                                138,687,000 
        convertible series a preferred, 0.00001 par value...
      		                                 
        related party accounts payable
      		                               730,000  
        contingent royalty obligation payable to related party
      		                               40,600,000  
        contingent promissory note payable to related party
      		                               16,149,000  
        restricted cash
      		                                 
        liabilities and stockholder’s deficit
      		                                 
        stockholder’s deficit
      		                                 
        total stockholder’s deficit
      		                                -75,543,000 
        total liabilities and stockholder’s deficit
      		                                152,233,000 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 
                                        
          cash flows from operating activities
        		                                
          net loss
        		130,000 -15,737,000 -17,142,000 -18,892,000 -6,791,000 -19,170,000 -11,350,000 -13,109,000 -11,831,000 -16,923,000 -18,140,000 -14,791,000 -13,164,000 -20,276,000   -18,177,000 -19,433,000   -110,694,000 -11,459,000 -21,125,000 -19,735,000 -14,508,000 -26,984,000 -37,567,000 -10,975,000 -12,442,000 -11,830,000   
          adjustments to reconcile net loss to net cash from operating activities:
        		                                
          depreciation and amortization
        		2,254,000 1,951,000 1,738,000 1,563,000 1,374,000 1,087,000 1,427,000 1,409,000 1,373,000 1,311,000 1,247,000 1,202,000 1,027,000 920,000 853,000 922,000 920,000 923,000 1,746,000 2,033,000 1,876,000 1,744,000 1,658,000 1,749,000 1,468,000 1,202,000 978,000 484,000 2,000 3,000   
          stock-based compensation
        		5,147,000 5,135,000 4,488,000 5,928,000 6,171,000 5,220,000 5,784,000 5,079,000 4,397,000 4,596,000 4,171,000 3,294,000 2,412,000 2,483,000 2,979,000 2,959,000 2,649,000 2,476,000 2,861,000 1,590,000 2,630,000 2,952,000 2,374,000 2,628,000 2,537,000 2,526,000 2,457,000 1,998,000 1,860,000 1,481,000 2,624,000 1,006,000 
          provision for credit losses and inventory
        		                                
          amortization of operating lease right-of-use assets
        		335,000 330,000 309,000 263,000 238,000 184,000 153,000 148,000 144,000 166,000 215,000 209,000 202,000 197,000 191,000 185,000 180,000 176,000 170,000 166,000 164,000 160,000 161,000 169,000 171,000 179,000 304,000 219,000     
          amortization of debt discount and issuance costs
        		343,000 336,000 309,000 301,000 298,000 290,000 282,000 277,000 273,000 266,000 279,000 298,000 281,000 272,000 270,000 263,000 59,000 302,000 294,000 286,000 698,000 703,000 643,000 647,000 643,000 624,000 608,000 281,000     
          deferred income taxes
        		27,000 -21,000 20,000 -5,000 -23,000 0 -3,000 5,000     -3,000 -4,000 6,000 -17,000     -154,000 -11,000 -66,000 256,000 -156,000 -149,000 -227,000 -14,523,000     
          revaluation of contingent royalty obligation payable to evolus founders
        		-4,511,000 -107,000 -3,914,000 2,151,000  2,428,000 1,605,000 1,578,000  1,802,000 1,682,000 1,648,000  1,216,000 1,414,000 1,316,000  1,400,000 1,381,000 1,268,000  -2,471,000 2,433,000 -9,884,000  1,795,000       
          non-cash in-process research and development expense
        		                                
          other adjustments to operating activities
        		236,000 251,000                               
          changes in operating assets and liabilities:
        		                                
          inventories
        		4,659,000 -11,492,000 -8,341,000 4,050,000 979,000 -1,476,000 -1,560,000 5,309,000 4,847,000 4,956,000 848,000 -6,458,000 4,595,000 -2,658,000 -7,054,000 -5,571,000 4,182,000 -7,181,000 -3,129,000 3,149,000 3,006,000 1,266,000 2,199,000 -1,929,000 1,743,000 5,297,000 -8,944,000 -2,578,000     
          accounts receivable
        		-4,792,000 -4,936,000 -958,000 -823,000 -3,829,000 -2,383,000 -9,491,000 -3,899,000 -151,000 -2,480,000 -5,610,000 -1,280,000 -1,763,000 -518,000 -4,500,000 -2,608,000 -1,456,000 -1,613,000 -3,751,000 1,254,000 2,092,000 -2,582,000 1,757,000 -2,352,000 -3,842,000 -5,796,000       
          prepaid expenses
        		900,000 188,000 -1,340,000 -103,000 50,000 2,108,000 171,000 22,000 -2,045,000 642,000 -138,000 -257,000 -246,000 3,750,000 -2,873,000 549,000  1,253,000 -273,000 -636,000             
          accounts payable
        		2,046,000 4,112,000 -777,000 4,722,000 -2,889,000 3,526,000 -1,155,000 909,000 -5,806,000 1,364,000 283,000 3,142,000 -1,370,000 -2,056,000 2,923,000 1,471,000 1,525,000 -763,000 259,000 -1,808,000 5,165,000   332,000 -553,000   305,000 897,000 -93,000 266,000 205,000 
          accrued expenses
        		3,954,000 2,517,000 1,337,000 -14,172,000 5,877,000 2,160,000 7,851,000 -8,874,000 7,100,000 2,529,000 2,075,000 -2,685,000 -5,089,000 1,346,000 7,398,000 -8,854,000 6,557,000 -922,000 11,791,000 3,465,000 2,678,000   -3,949,000 -4,742,000   2,667,000 -1,092,000 1,890,000 574,000 1,361,000 
          accrued litigation settlement
        		        0 0 0 -5,000,000 0 0 0 -15,000,000 0                
          operating lease liabilities
        		-212,000 -290,000 -177,000 -79,000 -194,000 -169,000 -182,000 -171,000 -159,000 -198,000 -280,000 -270,000 -254,000 -248,000 -243,000 -232,000 -219,000 -213,000 -209,000 -197,000 -178,000 -174,000 -201,000 -181,000 -123,000 -122,000 -187,000 -222,000     
          other operating assets
        		-240,000 884,000                               
          net cash from operating activities
        		12,827,000 -14,669,000 -24,791,000 -15,632,000 4,808,000 -5,722,000 -6,470,000 -10,615,000 813,000 -924,000 -13,310,000 -20,587,000 -8,774,000 -17,051,000 -20,888,000 -38,199,000 -9,044,000 -32,125,000 16,116,000 -8,335,000 -2,266,000 -13,713,000 -13,945,000 -27,947,000 -15,922,000 -25,103,000 -33,158,000 -19,200,000 -12,006,000 -5,797,000 -5,663,000 -2,201,000 
          capital expenditures
        		-1,479,000 -955,000 -688,000 -319,000 -438,000 -313,000 -465,000 -256,000 -209,000 -29,000 -8,000 -227,000 -866,000 -509,000 -231,000 -12,000 0 0 0  -17,000 -121,000 -112,000 -565,000 1,000 0 0 0 0 0 0 0 
          free cash flows
        		11,348,000 -15,624,000 -25,479,000 -15,951,000 4,370,000 -6,035,000 -6,935,000 -10,871,000 604,000 -953,000 -13,318,000 -20,814,000 -9,640,000 -17,560,000 -21,119,000 -38,211,000 -9,044,000 -32,125,000 16,116,000  -2,283,000 -13,834,000 -14,057,000 -28,512,000 -15,921,000 -25,103,000 -33,158,000 -19,200,000 -12,006,000 -5,797,000 -5,663,000 -2,201,000 
          cash flows from investing activities
        		                                
          purchases of property and equipment
        		-1,479,000 -955,000 -688,000 -319,000 -438,000 -313,000 -465,000 -256,000 -209,000 -29,000 -8,000 -227,000 -866,000 -509,000 -231,000 -12,000     -17,000 -121,000 -112,000 -565,000 1,000 0   0 0   
          additions to capitalized software
        		-687,000 -1,203,000 -1,579,000 -1,542,000 -924,000 -1,097,000 -789,000 -541,000 -152,000 -510,000 -208,000 -284,000 -525,000 -390,000 -157,000 -249,000 3,000 21,000 -386,000 -215,000 -282,000 -578,000 -528,000 -935,000 -1,142,000 -639,000 -1,618,000 -823,000     
          net cash from investing activities
        		-2,166,000 -2,158,000 -2,267,000 -1,861,000 -1,362,000 -1,410,000 -1,254,000 -797,000 -361,000 -539,000 -216,000 -511,000 -1,391,000 -899,000 -388,000 -261,000 -390,000 21,000 -386,000 4,785,000 19,701,000 29,301,000 9,380,000 -46,188,000 13,974,000 34,390,000 8,227,000 -80,025,000 0 0   
          cash flows from financing activities
        		                                
          payment of contingent royalty obligation to evolus founders
        		0 -1,786,000 -2,051,000 -2,365,000 -1,829,000 -2,005,000 -1,778,000 -1,829,000 -1,499,000 -1,479,000 -1,251,000 -1,308,000 -1,016,000 -1,114,000 -1,016,000 -1,039,000 -802,000 -783,000 -983,000 -529,000 0 -233,000 -315,000 -583,000 -395,000 -69,000       
          proceeds from issuance and modification of debt instruments
        		0 0                               
          payments for debt modification fees and debt issuance costs
        		                                
          proceeds from follow-on offering
        		                                
          payments for offering costs
        		    0 0           0 0           0 -300,000 -74,000 -686,000 
          issuance of common stock in connection with incentive equity plan
        		81,000 18,000 323,000 742,000  589,000 2,300,000 487,000 29,000 60,000 109,000 26,000 0 355,000 167,000 17,000 1,000 -1,000 644,000 11,000     1,346,000 314,000       
          payment of finance lease obligations
        		                                
          tax withholding paid on behalf of employees for net share settlement
        		                                
          net cash from financing activities
        		77,000 -1,772,000 20,663,000 -1,631,000 -1,313,000 -1,416,000 4,481,000 45,662,000 23,522,000 -1,419,000 23,820,000 -1,282,000 -1,516,000 -759,000 -849,000 -1,022,000 47,894,000 8,163,000 93,836,000 -76,841,000 0 39,767,000 -315,000 -1,105,000 72,724,000 -460,000 853,000 60,430,000 0 67,380,000 -313,000 51,771,000 
          effect of exchange rates on cash and cash equivalents
        		-435,000 384,000                               
          net increase in cash and cash equivalents
        		10,303,000 -18,215,000                               
          cash and cash equivalents, beginning of period
        		0 0 0 86,952,000 0 0 0 62,838,000 0 0 0 53,922,000 0 0 0 146,256,000 0 0 0 102,562,000 0 0 0 109,892,000 0 0 0 93,162,000     
          cash and cash equivalents, end of period
        		10,303,000 -18,215,000 -6,156,000 67,894,000 1,917,000 -8,636,000 -3,287,000 96,958,000 24,153,000 -3,020,000 10,242,000 31,463,000 -11,650,000 -18,912,000 -22,187,000 106,671,000 38,460,000 -23,941,000 109,566,000 22,171,000 17,435,000 55,355,000 -4,880,000 34,652,000 70,776,000 8,827,000 -24,078,000 54,367,000     
          provision for bad debts
        		 2,210,000 703,000 1,051,000 790,000 889,000 582,000 188,000 86,000 1,012,000 69,000 273,000 235,000 624,000 274,000 465,000 88,000 188,000 -297,000 610,000 -373,000 -168,000 0 2,607,000         
          payments for debt modification fees and costs
        		 0                               
          payment of financing lease obligation
        		 -4,000                               
          other
        		   146,000                             
          changes in assets and liabilities:
        		                                
          other assets
        		   -1,733,000 1,192,000 -416,000 -584,000 514,000 -974,000 33,000 -11,000 88,000  -2,099,000 945,000 3,454,000   -4,626,000 -1,657,000 201,000 1,105,000 98,000 93,000         
          proceeds from follow-on offering, net of underwriters fees
        		     0 4,207,000 47,004,000          0               
          tax withholding paid on behalf of employees for stock-based awards
        		   -8,000                        -58,000     
          effect of exchange rates on cash
        		   66,000  -88,000 -44,000 -130,000 179,000 -138,000 -52,000 -79,000 31,000 -203,000 -62,000 -103,000                 
          change in cash and cash equivalents
        		   -19,058,000 1,917,000 -8,636,000 -3,287,000 34,120,000 24,153,000 -3,020,000 10,242,000 -22,459,000 -11,650,000 -18,912,000 -22,187,000 -39,585,000 38,460,000 -23,941,000 109,566,000 -80,391,000 17,435,000 55,355,000 -4,880,000 -75,240,000 70,776,000 8,827,000 -24,078,000 -38,795,000     
          revaluation of contingent royalty obligation to evolus founders
        		                                
          proceeds from issuance of long-term debt, net of discounts
        		        25,000,000 0               0 0 0 73,906,000     
          payments for debt issuance costs
        		        -8,000 0               0 0 0 -2,205,000     
          proceeds from follow-on offering, net of underwriting fees
        		                                
          cash proceeds from exercise of stock options
        		                                
          amortization of discount on short-term investments
        		                    -7,000 -30,000 -221,000 -169,000   -466,000 -120,000     
          loss from extinguishment of debts
        		                0 0 0 968,000             
          other current assets
        		                                
          maturities of short-term investments
        		                0 0 0 5,000,000 20,000,000 30,000,000 35,000,000 5,000,000 30,000,000 40,000,000       
          repayment of long term debt
        		                0 0 0 -76,323,000             
          repayment of promissory note payable to evolus founders
        		                                
          proceeds from atm sales of shares
        		                0 8,947,000               
          paid-in-kind interest on convertible note
        		                 -1,000 0 273,000 303,000            
          net income
        		               -17,501,000    6,401,000            -6,162,000 
          consideration receivable from daewoong
        		                   -25,500,000             
          non-cash portion of accrued settlement expenses
        		                                
          prepaid expenses and other current assets
        		                    -1,009,000 -1,755,000 -697,000 1,771,000 -468,000 591,000 -348,000 -1,649,000 -253,000 115,000 -498,000 -356,000 
          purchases of short-term investments
        		                    0 0 -24,980,000 -49,688,000 -14,885,000 -4,971,000 -14,809,000 -79,202,000     
          proceeds from issuance of convertible note
        		                    0            
          payment for debt obligation
        		                    0 0 0 -522,000 -339,000        
          accrued settlement expenses
        		                                
          milestone payment for intangible assets
        		                        -1,000,000 0 0 -2,000,000     
          proceeds from issuance of term loan, net of discounts
        		                                
          accounts payable and accrued expenses
        		                                
          provisions for rebate and coupon programs
        		                        5,654,000        
          deferred rent
        		                            -5,000 -3,000 -3,000 -2,000 
          proceeds from initial public offering, net of underwriting fees
        		                                
          related party borrowings
        		                            0 0 0 1,127,000 
          payments on related party borrowings
        		                            0 0 0 -5,000,000 
          accretion of discount on short-term investments
        		                                
          proceeds from initial public offering, net of underwriters fees
        		                             0 0 56,330,000 
          revaluation of contingent royalty obligation payable to evolus founders, a related party
        		                           4,913,000  2,300,000   
          related party accounts payable
        		                               730,000 
          payment of contingent royalty obligation to evolus founders, a related party
        		                           -9,213,000     
          interest expense
        		                            114,000 321,000 321,000 107,000 
          tax benefit from therapeutic option right
        		                                
          revaluation of contingent royalty obligation to evolus founders, a related party
        		                                
          change in cash and restricted cash
        		                            -12,006,000 61,583,000   
          cash and restricted cash, beginning of period
        		                                
          cash, end of period
        		                            -12,006,000 61,583,000   
          supplemental disclosure of cash flow information
        		                                
          noncash financing activities:
        		                                
          related party receivable
        		                            0 0 0 73,690,000 
          note obligation
        		                            0 0 0 -140,688,000 
          contingent royalty obligation payable to evolus founders, a related party
        		                            0 0   
          contingent promissory note payable to evolus founders, a related party
        		                            0 0   
          capital contribution from parent, convertible note write-off
        		                            0 0 0 66,998,000 
          capital distribution to parent
        		                                
          capital contribution from parent, forgiveness of related party borrowings
        		                            0 0 0 13,188,000 
          capital contribution from parent - therapeutic option right, net of tax
        		                                
          deferred offering costs accrued, unpaid
        		                                
          deferred offering costs
        		                            0    
          accounts payable, paid by parent
        		                            0 0 0 -163,000 
          income tax expense
        		                             19,000 12,000 10,000 
          minimum tax withholding paid on behalf of employees for share-based awards
        		                             0   
          cash and restricted cash, beginning
        		                                
          non-cash financing activities:
        		                                
          capital distribution from parent
        		                                
          deferred ipo costs
        		                              0 -2,885,000 
          deferred offering costs, unpaid
        		                              52,000 -74,000 
          adjustments to reconcile net income to net cash from operating activities:
        		                                
          revaluation of contingent royalty obligation payable to related party
        		                               900,000 
          change in cash, cash equivalents, and restricted cash
        		                               49,570,000 
          cash, cash equivalents, and restricted cash, beginning
        		                                
          cash and cash equivalents, ending
        		                               49,570,000 
          contingent royalty obligation payable to related party
        		                               39,700,000 
          contingent promissory note payable to related party
        		                               16,042,000 
          •
        		                                
          adjustments to reconcile net income to net cash from operating activities
        		                                
          changes in assets and liabilities
        		                                
          release (payment) of restricted cash
        		                                
          deemed distribution
        		                                
          capital contribution - therapeutic option right, net of tax